title: Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus.
authors.forename: O
authors.initials: O
authors.lastname: De Pità
authors.forename: A M
authors.initials: AM
authors.lastname: Bellucci
authors.forename: M
authors.initials: M
authors.lastname: Ruffelli
authors.forename: C R
authors.initials: CR
authors.lastname: Girardelli
authors.forename: P
authors.initials: P
authors.lastname: Puddu
mesh_terms: D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D003176:Complement C3 / Q000032:analysis; D004247:DNA / Q000032:analysis; D005260:Female; D019085:Fluorescent Antibody Technique, Direct; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D012867:Skin / Q000276:immunology / Q000473:pathology*; D017211:Treatment Failure
chemical_list: D000974:Antibodies, Antinuclear; D003176:Complement C3; D016756:Immunoglobulins, Intravenous; D004247:DNA